InsidersTradesSigma
Eargo, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Eargo, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Eargo, Inc. has published 76 public disclosures. The latest transaction was filed on 20 February 2024 (Disposition). Among the most active insiders: Brownie William. All data is accessible without an account.
76
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€3m
37 ops.
Sell Volume
40Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 February 2024
Declarations76 total
32 sharesCommon StockSEC:0000950103-24-002447:0
25,463 sharesCommon StockSEC:0000950103-24-002453:0
38 sharesCommon StockSEC:0000950103-24-002455:0
1,029 shares@ US$2.5960.1% of flowCommon StockSEC:0001209191-23-056967:0
33 shares@ US$2.600.1% of flowCommon StockSEC:0001209191-23-056456:0
3 shares@ US$2.560.2% of flowCommon StockSEC:0001209191-23-055742:0
14 shares@ US$2.560.0% of flowCommon StockSEC:0001209191-23-055738:0
2,842 shares@ US$2.557.4% of flowCommon StockSEC:0001209191-23-055740:0
6,114 shares@ US$2.55214.4% of flowCommon StockSEC:0001209191-23-055334:0
3 shares@ US$3.230.2% of flowCommon StockSEC:0001209191-23-046240:0
14 shares@ US$3.230.0% of flowCommon StockSEC:0001209191-23-046246:0
19 shares@ US$3.23530.1% of flowCommon StockSEC:0001209191-23-046243:0
19 shares@ US$4.69010.1% of flowCommon StockSEC:0001209191-23-030591:0
3 shares@ US$4.69010.3% of flowCommon StockSEC:0001209191-23-030590:0
58 shares@ US$4.69010.2% of flowCommon StockSEC:0001209191-23-030605:0
14 shares@ US$4.69010.1% of flowCommon StockSEC:0001209191-23-030604:0
64 shares@ US$7.37010.4% of flowCommon StockSEC:0001209191-23-011607:0
15 shares@ US$7.37010.1% of flowCommon StockSEC:0001209191-23-011611:0
21 shares@ US$7.37010.2% of flowCommon StockSEC:0001209191-23-011623:0
4 shares@ US$7.42010.7% of flowCommon StockSEC:0001209191-23-011615:0
2,521 shares@ US$0.5030.5% of flowCommon StockSEC:0000899243-22-036999:0
71,363 shares@ US$0.50100.0% of flowCommon StockSEC:0000899243-22-037001:0
4,995 shares@ US$0.502.7% of flowCommon StockSEC:0000899243-22-037000:0
173,812 shares@ US$0.5090.1% of flowCommon StockSEC:0000899243-22-036998:0
86 shares@ US$0.51481.1% of flowCommon StockSEC:0000899243-22-036550:0
25 of 76 declarations
About Eargo, Inc.
Eargo, Inc. is a United States medical-device company listed on the NASDAQ market, with an investment profile centered on hearing health and consumer-oriented medtech. Founded in 2010 as Aria Innovations, Inc. and renamed Eargo in 2014, the company is headquartered in San Jose, California, in the United States. Its positioning is that of a specialized hearing-care brand combining miniaturized industrial design, ease of use, and remote customer support. Eargo’s core business is the design, commercialization, and sale of virtually invisible, rechargeable, completely in-the-canal hearing aids, primarily intended for adults with mild to moderate hearing loss. Historically, the company has relied on a direct-to-consumer model supported by inside sales consultants, dedicated customer service teams, and personalized remote assistance from hearing professionals. That approach is designed to address the three major barriers that have traditionally limited hearing-aid adoption: social stigma, accessibility, and cost. On the product side, Eargo has focused on successive generations of hearing aids, each adding improvements in sound quality, comfort, durability, connectivity, and ease of fitting and use. Recent launches show that product iteration remains central to the strategy, including the Eargo 8 flagship device and related app/software updates that enhance the user experience. This cadence matters competitively because the OTC and premium hearing-aid market remains fragmented and highly sensitive to product design, customer onboarding, and post-sale support. From a competitive standpoint, Eargo sits at the intersection of healthcare, medtech, and consumer electronics. Its competitive edge is less about scale and more about product differentiation, brand identity, and a remote-first service model. The company is targeting an underpenetrated U.S. market where demand for more accessible hearing solutions remains structurally attractive. A recent notable point is Eargo’s continued 2025 emphasis on Eargo 8, supported by product communications and external recognition, underscoring management’s effort to reinforce a more premium, technology-driven brand image. For investors, Eargo remains a niche healthcare small cap whose performance depends on execution in commercial growth, product innovation, and the evolution of the U.S. hearing-aid market.
